Boothbay Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boothbay Fund Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,500	Closed	-$1.55M	–	2406
2025 Q4	$1.55M	Buy	67,500 +34,500	+105%	+$1.13M	0.02%	661
2025 Q3	$993K	Sell	33,000 -75,000	-69%	-$2.25M	0.01%	841
2025 Q2	$3.93M	Buy	108,000 +77,700	+256%	+$2.8M	0.08%	347
2025 Q1	$1.1M	Buy	+30,300	New	+$1.26M	0.03%	596
2021 Q2	–	Sell	-22	Closed	-$250K	–	2067
2021 Q1	$250K	Buy	+22	New	+$3K	0.01%	1274

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Boothbay Fund Management's RARE Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 141,978 shares worth $2.97M. The stake represents 0.04% of the portfolio and ranks #480 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in RARE as recently as Q3 2025.

Boothbay Fund Management first reported a position in RARE in Q4 2019 and has held it in 9 quarters since. The position peaked at $3.03M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Boothbay Fund Management held 141,978 shares of Ultragenyx Pharmaceutical worth $2.97M as of Q1 2026.
Ultragenyx Pharmaceutical was a new Boothbay Fund Management position in Q1 2026.
Ultragenyx Pharmaceutical made up 0.04% of Boothbay Fund Management's portfolio in Q1 2026, its #480 holding.
Boothbay Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 9 quarters since.
Boothbay Fund Management's Ultragenyx Pharmaceutical position peaked at $3.03M in Q3 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.